Clinical Trials
91 trialsDonor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Dana-Farber Cancer Institute
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
Second Affiliated Hospital of Soochow University
1703/1801
Medical College of Wisconsin
FluBuATG
Dartmouth-Hitchcock Medical Center
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Alliance for Clinical Trials in Oncology
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Alliance for Clinical Trials in Oncology
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
LVPK
BTG International Inc.
ALCL 99
Gustave Roussy, Cancer Campus, Grand Paris
Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Milton S. Hershey Medical Center
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
UNICANCER
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Therapeutic Advances in Childhood Leukemia Consortium
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
M.D. Anderson Cancer Center
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
M.D. Anderson Cancer Center
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
M.D. Anderson Cancer Center
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
University of Texas Southwestern Medical Center
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
M.D. Anderson Cancer Center
Bone Marrow Transplantation in Treating Patients With Leukemia
Masonic Cancer Center, University of Minnesota
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
Northwestern University
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
Children's Hospital of Philadelphia
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
University of Texas Southwestern Medical Center
Combination Chemotherapy in Treating Patients With Lymphoma
M.D. Anderson Cancer Center
Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Masonic Cancer Center, University of Minnesota
Bu Flu TBI
OHSU Knight Cancer Institute
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
LCCC0510
UNC Lineberger Comprehensive Cancer Center
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
UNC Lineberger Comprehensive Cancer Center
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Dana-Farber Cancer Institute
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Protocol-B
OHSU Knight Cancer Institute
Protocol-A
OHSU Knight Cancer Institute
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Memorial Sloan Kettering Cancer Center
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
Dana-Farber Cancer Institute
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
Massachusetts General Hospital
Tandem Auto-Allo Transplant for Lymphoma
Massachusetts General Hospital
Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma
Trans Tasman Radiation Oncology Group
Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
University of Miami
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology